title: Effects of chronic expression of the HIV-induced protein, transactivator of transcription, on circadian activity rhythms in mice, with or without morphine.
abstract: Patients with human immunodeficiency virus (HIV) infection exhibit changes in sleep patterns, motor disorders, and cognitive dysfunction; these symptoms may be secondary to circadian rhythm abnormalities. Studies in mice have shown that intracerebral injection of an HIV protein, transactivator of transcription (Tat), alters the timing of circadian rhythms in a manner similar to light. Therefore, we tested the hypothesis that chronic Tat expression alters circadian rhythms, especially their entrainment to a light-dark (LD) cycle, by using transgenic mice in which Tat expression in the brain was induced via a doxycycline (DOX)-sensitive, glial fibrillary-associated, protein-restricted promoter. Because opiate substance abuse, which shares comorbidity with HIV infection, also disrupts sleep, a final experiment assessed the effects of morphine exposure on circadian rhythms in wild-type and Tat transgenic mice. Mice housed in cages equipped with running wheels were fed chow with or without DOX. Experiment 1 revealed a small but significant (P < 0.05) difference between groups in the phase angle of entrainment and a 15% decrease in the wheel running in the DOX group (P < 0.005). During exposure to constant darkness, DOX did not alter the endogenous period length of the circadian rhythm. Experiment 2 investigated the effect of DOX on circadian rhythms in wild-type and Tat(+) mice during exposure to a normal or phase-shifted LD cycle, or morphine treatment without any change in the LD cycle. Tat induction significantly decreased wheel running but did not affect entrainment to the normal or shifted LD cycle. Morphine decreased wheel running without altering the phase angle of entrainment, and the drug's effects were independent of Tat induction. In conclusion, these findings suggest that chronic brain expression of Tat decreases locomotor activity and the amplitude of circadian rhythms, but does not affect photic entrainment or reentrainment of the murine circadian pacemaker.
authors.affiliation: Dept. of Anatomy and Neurobiology, Univ. of Kentucky Medical Center, 800 Rose St., Lexington, KY 40536-0298, USA. marilyn.duncan@uky.edu
authors.forename: Marilyn J
authors.initials: MJ
authors.lastname: Duncan
authors.forename: Annadora J
authors.initials: AJ
authors.lastname: Bruce-Keller
authors.forename: Clayton
authors.initials: C
authors.lastname: Conner
authors.forename: Pamela E
authors.initials: PE
authors.lastname: Knapp
authors.forename: Ruquiang
authors.initials: R
authors.lastname: Xu
authors.forename: Avindra
authors.initials: A
authors.lastname: Nath
authors.forename: Kurt F
authors.initials: KF
authors.lastname: Hauser
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002940:Circadian Rhythm / Q000187:drug effects / Q000235:genetics* / Q000502:physiology*; D003624:Darkness; D004318:Doxycycline / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009020:Morphine / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D054322:tat Gene Products, Human Immunodeficiency Virus / Q000096:biosynthesis* / Q000235:genetics* / Q000502:physiology
chemical_list: D000701:Analgesics, Opioid; D000900:Anti-Bacterial Agents; D054322:tat Gene Products, Human Immunodeficiency Virus; D009020:Morphine; D004318:Doxycycline
references.citation: Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15138-43
references.pmid: 17846423
references.citation: Lancet. 1986 Jul 12;2(8498):89-92
references.pmid: 2873389
references.citation: AIDS. 1998 Oct 1;12(14):1845-50
references.pmid: 9792385
references.citation: Genome Biol. 2007;8(6):R128
references.pmid: 17598886
references.citation: Indian J Med Res. 2000 Nov;112:173-7
references.pmid: 12452125
references.citation: J Acquir Immune Defic Syndr. 2002 Oct 1;31 Suppl 2:S35-42
references.pmid: 12394781
references.citation: Neurobiol Learn Mem. 2001 Jan;75(1):51-62
references.pmid: 11124046
references.citation: J Neurosci. 2003 Sep 10;23(23):8417-22
references.pmid: 12968004
references.citation: Am J Physiol. 1998 Dec;275(6):H2334-7
references.pmid: 9843836
references.citation: Science. 1994 Dec 9;266(5191):1713-7
references.pmid: 7527589
references.citation: Cancer Res. 2004 Nov 1;64(21):7879-85
references.pmid: 15520194
references.citation: J Circadian Rhythms. 2006 Aug 22;4:9
references.pmid: 16925815
references.citation: Curr Pharm Des. 2006;12(9):1023-44
references.pmid: 16515484
references.citation: Neuroreport. 1995 Dec 29;7(1):209-12
references.pmid: 8742453
references.citation: Ann N Y Acad Sci. 2001 Jun;937:27-49
references.pmid: 11458539
references.citation: AIDS. 1995 Sep;9(9):1043-50
references.pmid: 8527076
references.citation: Physiol Behav. 1985 Jun;34(6):883-7
references.pmid: 4059376
references.citation: J Neurochem. 2007 Feb;100(3):567-86
references.pmid: 17173547
references.citation: Neurosci Lett. 1989 Apr 24;99(1-2):55-60
references.pmid: 2664580
references.citation: Behav Neurosci. 1999 Oct;113(5):991-7
references.pmid: 10571481
references.citation: J Pharmacol Exp Ther. 1984 Nov;231(2):306-11
references.pmid: 6092613
references.citation: J Acquir Immune Defic Syndr. 2002 Oct 1;31 Suppl 2:S62-9
references.pmid: 12394784
references.citation: J Neurosci. 2002 Sep 1;22(17):7326-30
references.pmid: 12196553
references.citation: Brain. 1998 Nov;121 ( Pt 11):2043-52
references.pmid: 9827765
references.citation: Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):15072-7
references.pmid: 9844017
references.citation: J Neurosci. 1997 Jan 15;17(2):667-75
references.pmid: 8987789
references.citation: J Biol Chem. 2003 Apr 11;278(15):13512-9
references.pmid: 12551932
references.citation: NIDA Res Monogr. 1987;76:53-62
references.pmid: 3125471
references.citation: Eur J Neurosci. 2005 Jun;21(11):2958-66
references.pmid: 15978007
references.citation: Am J Physiol Regul Integr Comp Physiol. 2005 Sep;289(3):R656-62
references.pmid: 15860648
references.citation: J Neurosci. 1999 Jun 15;19(12):5124-30
references.pmid: 10366645
references.citation: Drug Alcohol Depend. 1997 Oct 25;48(1):9-16
references.pmid: 9330916
references.citation: AIDS Res Hum Retroviruses. 1997 Sep 20;13(14):1243-9
references.pmid: 9310292
references.citation: Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):51-7
references.pmid: 11420068
references.citation: Cold Spring Harb Symp Quant Biol. 1960;25:159-84
references.pmid: 13736116
references.citation: Nature. 1984 Mar 8-14;308(5955):186-8
references.pmid: 6700721
references.citation: Occup Environ Med. 1999 Jan;56(1):46-50
references.pmid: 10341746
references.citation: Clin Cancer Res. 2000 Aug;6(8):3038-45
references.pmid: 10955782
references.citation: J Acquir Immune Defic Syndr (1988). 1993 Nov;6(11):1238-47
references.pmid: 8229657
references.citation: Glia. 2008 Oct;56(13):1414-27
references.pmid: 18551626
references.citation: Pathol Biol (Paris). 2003 Jun;51(4):216-9
references.pmid: 12852994
references.citation: J Biol Rhythms. 1998 Oct;13(5):430-6
references.pmid: 9783234
references.citation: Brain Res Brain Res Rev. 2005 Nov;49(3):429-54
references.pmid: 16269313
references.citation: Nat Neurosci. 2001 Jun;4(6):567-8
references.pmid: 11369936